UNASSIGNED: 4695 Background: Options for @entity1 with progression of @entity263 following @entity342 ablation and chemotherapy are limited. Prior studies have demonstrated the efficacy of @entity172 in this group of @entity1 , but safe and effective agents are limited. Given prior data demonstrating the safety and ease of using an @entity53 patch, we tested the hypothesis that the patch would be a safe and effective option for @entity1 with hormone and chemotherapy @entity263 . METHODS: In this ongoing study, ten @entity1 with hormone @entity263 who had progressed after at least one chemotherapy regimen were enrolled. @entity1 were treated with two transdermal patches (total daily dose: 0.2 mg of @entity53 ) changed weekly. RESULTS: 7/10 @entity1 received one prior and 3/10 two or more prior chemotherapy regimens. Median age was 64 years (range 57 to 76). @entity1486 ( @entity1486 ) decreased in 5/10 @entity1 (mean decrease 27%). 2/3 @entity1 that were treated for at least 3 months had stable disease, as defined as < 25% increase over the first 3 months of therapy. 7/10 @entity1 remain on study. Therapy was well tolerated. There were no grade 2 or 3 adverse events. CONCLUSION: In @entity1 with hormone and chemotherapy @entity263 , transdermal @entity53 patches may offer a safe and active option of therapy, but further study is warranted and ongoing. No significant financial relationships to disclose.

A phase II salvage trial of transdermal @entity53 in the treatment of hormone and chemotherapy XXXX : A Cancer Institute of New Jersey Oncology Group Study NJ1803.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity263 :: ('MESH:D011471', 'Disease') :: ['refractory prostate cancer', 'prostate cancer'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity1486 :: ('354', 'Gene') :: ['PSA', 'Prostate specific antigen']
@entity263 :: (MESH:D011471,Disease) :: ['refractory prostate cancer']
